U.S. Markets closed

Cempra, Inc. (CEMP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
3.15+0.05 (+1.61%)
At close: 4:00PM EDT
People also watch
TTPHESPRFOLDPTCTCLVS
  • S
    Schwinger
    Schwinger
    Today I sold all my 3500 stocks with 3000 USD loss. This Piece of trash stock with that Kind of rubbish Management will go under 3 USD soon. It was the same Situation in the 4's USD range....Dont trust theses liars. You will get 1 new Stock for 15 old stocks. This is the fact. They don't care about existing Investors. Quit as Long as you can! GL
  • A
    Anonymous
    Anonymous

    MEGA OPP on this one ..
    SLNO (MC $25 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $25 Million
    Cash: $8 Million
    Price $0.51

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • U
    UpTech
    UpTech
    Hats off to Agamemnus. Nice work.
  • M
    Matthew
    Matthew
    Heeeeee dead.
  • K
    Ken
    Ken

    https://seekingalpha.com/article/4102673-cempra-combine-melinta-add-safest-effective-fluoroquinolone-ever-developed?v=1504090969&comments=show

    Cempra To Combine With Melinta, To Add The Safest And Most Effective Fluoroquinolone Ever Developed
    This is a companion/introductory article to one or more potentially future and more detailed articles bout the Cempra and Melinta merger. The new FDA guidance (
    seekingalpha.com
  • S
    Saltynacho
    Saltynacho
    Lets Not Forget - Fusidic Acid | Bone and Joint Infection Clinical Trial.
    Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections.
    This study is ongoing, but not recruiting participants.
    Catalyst - Estimated Primary Completion Date- October 2017 (Final data collection date for primary outcome measure)
  • S
    Saltynacho
    Saltynacho

    Cempra - Slowly it rose, cents by cents...........
    https://www.youtube.com/watch?v=8KpsUlvzbkk

    Abbott & Costello - The Niagara Falls Sketch (Slowly I Turned) - Amplified Volume
    www.youtube.com
  • G
    Gita
    Gita
    Is this merger beneficial for shareholders suggestions please
  • c
    charles
    charles
    POS Zaccardelli, his partners in crime, and the corrupt BOD are all dumping their stocks. Wise up people!!!
  • P
    Pete
    Pete
    Bail on the merger,
    dump management
    and get some competents in to run things!
  • G
    Guapo
    Guapo
    they definitely not getting my approval for the merger unless they remove these parachutes. If I crash, you crash. play it fair incompetent management.
  • G
    Gregory
    Gregory
    Can anyone enlighten me on the process and time frame of this reverse merger?

    Many thanks in advance for your response.
  • c
    charles
    charles
    Hard to believe how any of you longs can be surprised by the scoundrels running this dead company starting with "The Little Ape In Flats" and now incompetent Zaccardelli, his incompetent management and BOD.

    This company has engaged in lies, fraud, and corruption from its inception. When the Soli P3 trial failed, what did management do? They gave themselves promotions and salary increases. By December of this year, they will have gone thru $80M with nothing to show for it except looking out for themselves.

    Now they have given themselves golden parachutes and should all go to jail and you are surprised.

    When a company tells you who they are, believe them. They made themselves very clear. They told you they were con men, and you still brought into their BS. You have nobody to blame but yourselves. This was a scam from day 1.
  • b
    beachbum
    beachbum
    Management can write a book on how to destroy shareholder value, while paying themselves more money!!!
  • G
    Guapo
    Guapo
    seriously? where is this incompetent management drove this company to? the sewers?
  • m
    martin
    martin
    What does this company have other than cash? That will vanish after the "Golden Parachutes". I am surprised the founder of this company has not been sued by shareholders for withholding the liver enzyme debacle of the Antibiotic that was turned down by the FDA..
  • G
    Guapo
    Guapo
    will this turd ever go go back up?
  • b
    bill
    bill
    wonder what bacterial disease solithromycin and baxdela combo can cure
  • K
    Ken
    Ken
    Im actually beginning to think the market for ABSSSI /MRSA may be twice as large as for CABP.
    119,000 deaths for MRSA 59,000 for CABP.
    If Baxdella has twice the sales potential as Soli and we own half,then share price should be worth above $25 today.
  • b
    beachbum
    beachbum
    I bet that a lot of lawsuits will be forthcoming, it's the old raiding of the coffers!!!